Key clinical point: Proximal fractures, not just the hip, should be grounds for concern.
Major finding: Proximal fractures were associated with 50%-300% increases in mortality risk, compared with a control group of patients without fracture.
Study details: A retrospective analysis of a Danish population (212,498 women, 95,372 men).
Disclosures: Dr. Center has been on an advisory board for Amgen. Dr. Watts has been a speaker for Amgen and Radius and has conducted numerous clinical trials of osteoporosis drugs.
Center J et al. ENDO 2020, Abstract OR13-03.